Loading
A phase 3 trial testing JDQ443 in non-small-cell lung cancer, active and no longer recruiting.
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT05132075, led by Novartis Pharmaceuticals, and active but no longer recruiting on the registry. Official title: A Randomised, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer. Planned enrolment is 95 participants (actual). The study started in 2022-06-15 and primary completion is expected in 2026-08-25. No results have been posted on ClinicalTrials.gov.
Shares JDQ443, KRAS G12C-mutant non-small-cell lung cancer, Novartis, Non-small-cell lung cancer.
Shares JDQ443, KRAS G12C-mutant non-small-cell lung cancer, Novartis, Non-small-cell lung cancer.
Shares JDQ443, KRAS G12C-mutant non-small-cell lung cancer, Novartis, Non-small-cell lung cancer.
Shares JDQ443, Novartis, Non-small-cell lung cancer.
Shares KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer.
Shares KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer.
Shares KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer.
Shares KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer.